Patents by Inventor Jeffrey I. Weitz
Jeffrey I. Weitz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11871916Abstract: Vascular closure devices and methods for closing a blood vessel puncture site disposed at a distal end of a tissue tract are described. A combination of the body's own natural mechanism with chemical and/or biological agents is relied upon to accelerate the hemostatic process. Included are steps of introducing a closure device through the tissue tract and deploying an expansible member at a distal end of the device within the blood vessel to occlude the puncture site. A sealing member disposed proximal the expansible member is then displaced by retracting and tensioning a coil spring so as to expose a chemical and/or biological region or release region of the device. The retraction and tensioning of the coil spring is limited by a coupling member. Exposure of blood and tissue to the chemical and/or biological sealing member promotes the clotting processing to accelerate the occlusion process in the tract.Type: GrantFiled: July 15, 2022Date of Patent: January 16, 2024Assignee: Cardiva Medical, Inc.Inventors: Zia Yassinzadeh, Jeffrey I. Weitz, Alan Stafford
-
Publication number: 20220370055Abstract: Vascular closure devices and methods for closing a blood vessel puncture site disposed at a distal end of a tissue tract are described. A combination of the body's own natural mechanism with chemical and/or biological agents is relied upon to accelerate the hemostatic process. Included are steps of introducing a closure device through the tissue tract and deploying an expansible member at a distal end of the device within the blood vessel to occlude the puncture site. A sealing member disposed proximal the expansible member is then displaced by retracting and tensioning a coil spring so as to expose a chemical and/or biological region or release region of the device. The retraction and tensioning of the coil spring is limited by a coupling member. Exposure of blood and tissue to the chemical and/or biological sealing member promotes the clotting processing to accelerate the occlusion process in the tract.Type: ApplicationFiled: July 15, 2022Publication date: November 24, 2022Inventors: Zia Yassinzadeh, Jeffrey I. Weitz, Alan Stafford
-
Patent number: 11399815Abstract: Vascular closure devices and methods for closing a blood vessel puncture site disposed at a distal end of a tissue tract are described. A combination of the body's own natural mechanism with chemical and/or biological agents is relied upon to accelerate the hemostatic process. Included are steps of introducing a closure device through the tissue tract and deploying an expansible member at a distal end of the device within the blood vessel to occlude the puncture site. A sealing member disposed proximal the expansible member is then displaced by retracting and tensioning a coil spring so as to expose a chemical and/or biological region or release region of the device. The retraction and tensioning of the coil spring is limited by a coupling member. Exposure of blood and tissue to the chemical and/or biological sealing member promotes the clotting processing to accelerate the occlusion process in the tract.Type: GrantFiled: June 10, 2019Date of Patent: August 2, 2022Inventors: Zia Yassinzadeh, Jeffrey I. Weitz, Alan Stafford
-
Publication number: 20190388076Abstract: Vascular closure devices and methods for closing a blood vessel puncture site disposed at a distal end of a tissue tract are described. A combination of the body's own natural mechanism with chemical and/or biological agents is relied upon to accelerate the hemostatic process. Included are steps of introducing a closure device through the tissue tract and deploying an expansible member at a distal end of the device within the blood vessel to occlude the puncture site. A sealing member disposed proximal the expansible member is then displaced by retracting and tensioning a coil spring so as to expose a chemical and/or biological region or release region of the device. The retraction and tensioning of the coil spring is limited by a coupling member. Exposure of blood and tissue to the chemical and/or biological sealing member promotes the clotting processing to accelerate the occlusion process in the tract.Type: ApplicationFiled: June 10, 2019Publication date: December 26, 2019Inventors: Zia YASSINZADEH, Jeffrey I. WEITZ, Alan STAFFORD
-
Patent number: 10363021Abstract: Vascular closure devices and methods for closing a blood vessel puncture site disposed at a distal end of a tissue tract are described. A combination of the body's own natural mechanism with chemical and/or biological agents is relied upon to accelerate the hemostatic process. Included are steps of introducing a closure device through the tissue tract and deploying an expansible member at a distal end of the device within the blood vessel to occlude the puncture site. A sealing member disposed proximal the expansible member is then displaced by retracting and tensioning a coil spring so as to expose a chemical and/or biological region or release region of the device. The retraction and tensioning of the coil spring is limited by a coupling member. Exposure of blood and tissue to the chemical and/or biological sealing member promotes the clotting processing to accelerate the occlusion process in the tract.Type: GrantFiled: February 3, 2017Date of Patent: July 30, 2019Assignee: Cardiva Medical, Inc.Inventors: Zia Yassinzadeh, Jeffrey I. Weitz, Alan Stafford
-
Publication number: 20170202546Abstract: Vascular closure devices and methods for closing a blood vessel puncture site disposed at a distal end of a tissue tract are described. A combination of the body's own natural mechanism with chemical and/or biological agents is relied upon to accelerate the hemostatic process. Included are steps of introducing a closure device through the tissue tract and deploying an expansible member at a distal end of the device within the blood vessel to occlude the puncture site. A sealing member disposed proximal the expansible member is then displaced by retracting and tensioning a coil spring so as to expose a chemical and/or biological region or release region of the device. The retraction and tensioning of the coil spring is limited by a coupling member. Exposure of blood and tissue to the chemical and/or biological sealing member promotes the clotting processing to accelerate the occlusion process in the tract.Type: ApplicationFiled: February 3, 2017Publication date: July 20, 2017Inventors: Zia YASSINZADEH, Jeffrey I. WEITZ, Alan STAFFORD
-
Patent number: 9597066Abstract: Drug eluting vascular closure devices and methods for closing a blood vessel puncture site disposed at a distal end of a tissue tract are described. The devices and methods rely on a combination of the body's own natural mechanism to achieve hemostasis with chemical and/or biological agents to accelerate the hemostatic process. One method includes the steps of introducing a closure device through the tissue tract and deploying an expansible member at a distal end of the device within the blood vessel to occlude the puncture site. A chemical and/or biological sealing member disposed proximal the expansible member is then displaced so as to expose a chemical and/or biological region or release region of the device. At least one chemical and/or biological agent is thereafter released from the device and into the tissue tract to accelerate the occlusion process in the tract.Type: GrantFiled: September 9, 2015Date of Patent: March 21, 2017Assignee: CARDIVA MEDICAL, INC.Inventors: Zia Yassinzadeh, Jeffrey I. Weitz, Alan Stafford
-
Publication number: 20160249897Abstract: Drug eluting vascular closure devices and methods for closing a blood vessel puncture site disposed at a distal end of a tissue tract are described. The devices and methods rely on a combination of the body's own natural mechanism to achieve hemostasis with chemical and/or biological agents to accelerate the hemostatic process. One method includes the steps of introducing a closure device through the tissue tract and deploying an expansible member at a distal end of the device within the blood vessel to occlude the puncture site. A chemical and/or biological sealing member disposed proximal the expansible member is then displaced so as to expose a chemical and/or biological region or release region of the device. At least one chemical and/or biological agent is thereafter released from the device and into the tissue tract to accelerate the occlusion process in the tract.Type: ApplicationFiled: September 9, 2015Publication date: September 1, 2016Inventors: Zia YASSINZADEH, Jeffrey I. WEITZ, Alan STAFFORD
-
Patent number: 9179897Abstract: Drug eluting vascular closure devices and methods for closing a blood vessel puncture site disposed at a distal end of a tissue tract are described. The devices and methods rely on a combination of the body's own natural mechanism to achieve hemostasis with chemical and/or biological agents to accelerate the hemostatic process. One method includes the steps of introducing a closure device through the tissue tract and deploying an expansible member at a distal end of the device within the blood vessel to occlude the puncture site. A chemical and/or biological sealing member disposed proximal the expansible member is then displaced so as to expose a chemical and/or biological region or release region of the device. At least one chemical and/or biological agent is thereafter released from the device and into the tissue tract to accelerate the occlusion process in the tract.Type: GrantFiled: July 2, 2007Date of Patent: November 10, 2015Assignee: CARDIVA MEDICAL, INC.Inventors: Zia Yassinzadeh, Jeffrey I. Weitz, Alan Stafford
-
Publication number: 20080119438Abstract: The present invention provides compositions and methods for the treatment of cardiovascular diseases. More particularly, the present invention relates to modifying thrombus formation by administering an agent which, inter alia, is capable of (1) inactivating fluid-phase thrombin and thrombin which is bound either to fibrin in a clot or to some other surface by catalyzing antithrombin; and (2) inhibiting thrombin generation by catalyzing factor Xa inactivation by antithrombin III (ATIII). The compositions and methods of the present invention are particularly useful for preventing thrombosis in the circuit of cardiac bypass apparatus and in patients undergoing renal dialysis, and for treating patients suffering from or at risk of suffering from thrombus-related cardiovascular conditions, such as unstable angina, acute myocardial infraction (heart attack), cerebrovascular accidents (stroke), pulmonary embolism, deep vein thrombosis, arterial thrombosis, etc.Type: ApplicationFiled: July 25, 2005Publication date: May 22, 2008Inventors: Jeffrey I. Weitz, Jack Hirsh
-
Patent number: 6780850Abstract: The present invention is a complex of a polynucleotide having a property of specifically binding to a target protein together with a protein that stabilizes the polynucleotide from degradation and from clearance from the circulation in vivo. Methods for diagnostic imaging and therapeutic uses of the complex are disclosed.Type: GrantFiled: June 22, 2000Date of Patent: August 24, 2004Assignee: TRIUMFInventors: Alfred H. Dougan, Jeffrey I. Weitz
-
Publication number: 20040038932Abstract: The invention relates generally to compositions and methods for preventing or inhibiting thrombin generation or activity.Type: ApplicationFiled: July 9, 2003Publication date: February 26, 2004Inventors: Jack Hirsh, Kristian Johansen, Jeffrey I. Weitz
-
Patent number: 6132965Abstract: A method for diagnosing hyperhomocysteinemia by molecular genetic means is disclosed.Type: GrantFiled: January 30, 1998Date of Patent: October 17, 2000Assignee: Hamilton Civic Hospitals Research Development Inc.Inventors: Richard C. Austin, Jack Hirsh, Jeffrey I. Weitz
-
Patent number: 6075013Abstract: The present invention provides compositions and methods for the treatment of cardiovascular diseases. More particularly, the present invention relates to modifying thrombus formation by administering an agent which, inter alia, is capable of (1) inactivating fluid-phase thrombin and thrombin which is bound either to fibrin in a clot or to some other surface by catalyzing antithrombin; and (2) inhibiting thrombin generation by catalyzing factor Xa inactivation by antithrombin III (ATIII). The compositions and methods of the present invention are particularly usefull for preventing thrombosis in the circuit of cardiac bypass apparatus and in patients undergoing renal dialysis, and for treating patients suffering from or at risk of suffering from thrombus-related cardiovascular conditions, such as unstable angina, acute myocardial infarction (heart attack), cerebrovascular accidents (stroke), pulmonary embolism, deep vein thrombosis, arterial thrombosis, etc.Type: GrantFiled: June 5, 1998Date of Patent: June 13, 2000Assignee: Hamilton Civic Hospitals Research Development Inc.Inventors: Jeffrey I. Weitz, Jack Hirsh
-
Patent number: 6001820Abstract: The present invention provides compositions and methods for the treatment of cardiovascular diseases. More particularly, the present invention relates to modifying thrombus formation by administering an agent which, inter alia, is capable of (1) selectively inactivating thrombin which is bound either to fibrin in a clot or to some other surface, but which has only minimal inhibitory activity against free thrombin, i.e., fluid-phase thrombin; (2) inhibiting the assembly of the intrinsic tenase complex, thereby inhibiting the activation of Factor X by Factor IXa; and (3) inhibiting the activation of Factor IX by Factor XIa.Type: GrantFiled: June 6, 1997Date of Patent: December 14, 1999Assignee: Hamilton Civic Hospitals Research Development Inc.Inventors: Jack Hirsh, Jeffrey I. Weitz
-
Patent number: 5817461Abstract: A method for diagnosing hyperhomocysteinemia by molecular genetic means is disclosed.Type: GrantFiled: January 3, 1996Date of Patent: October 6, 1998Assignee: Hamilton Civic Hospitals Research Development Inc.Inventors: Richard C. Austin, Jack Hirsh, Jeffrey I. Weitz
-
Patent number: 5767269Abstract: The present invention generally relates to a processes for preparing low affinity, low molecular weight heparins (LA-LWM-heparins) which are endowed with pharmacological and therapeutic properties that are surprisingly advantageous. In one embodiment, the process comprises: (1) nitrous acid depolymerization of unfractionated heparin to yield low molecular weight heparin (LMWH); (2) oxidation of the resulting LMWH to open the ring structures the nonsulfated uronic acid moieties using, for example, sodium periodate; and (3) reduction of the oxidized LMWH to reduce the aldehydes (to alcohols) formed during the depolymerization and oxidation steps using, for example, sodium borohydride. The resulting LA-LMW-heparins are capable of inactivating thrombin bound to fibrin within a thrombus or clot, whereby the ability of clot-bound thrombin to catalytically promote further clot accretion is substantially diminished or eliminated.Type: GrantFiled: October 1, 1996Date of Patent: June 16, 1998Assignee: Hamilton Civic Hospitals Research Development Inc.Inventors: Jack Hirsh, Patrick N. Shaklee, James E. Knobloch, Jeffrey I. Weitz, Edward Young
-
Patent number: 5763427Abstract: The present invention provides compositions and methods for inactivating thrombin bound to fibrin within a thrombus or clot, whereby the ability of clot-bound thrombin to catalytically promote further clot accretion is substantially diminished or eliminated. The compositions and methods of the present invention are particularly useful for preventing thrombosis in the circuit of cardiac bypass apparatus and in patients undergoing renal dialysis, and for treating patients suffering from or at risk of suffering from thrombus-related cardiovascular conditions, such as unstable angina, acute myocardial infarction (heart attack), cerebrovascular accidents (stroke), pulmonary embolism, deep vein thrombosis, arterial thrombosis, etc.Type: GrantFiled: March 29, 1996Date of Patent: June 9, 1998Assignee: Hamilton Civic Hospitals Research Development Inc.Inventors: Jeffrey I. Weitz, Jack Hirsh, Edward Young
-
Patent number: 5744457Abstract: The present invention provides compositions and methods for inactivating thrombin bound to fibrin within a thrombus or clot, whereby the ability of clot-bound thrombin to catalytically promote further clot accretion is substantially diminished or eliminated. The compositions and methods of the present invention are particularly useful for preventing thrombosis in the circuit of cardiac bypass apparatus and in patients undergoing renal dialysis, and for treating patients suffering from or at risk of suffering from thrombus-related cardiovascular conditions, such as unstable angina, acute myocardial infarction (heart attack), cerebrovascular accidents (stroke), pulmonary embolism, deep vein thrombosis, arterial thrombosis, etc.Type: GrantFiled: October 6, 1995Date of Patent: April 28, 1998Assignee: Hamilton Civic Hospitals Research Development Inc.Inventors: Jeffrey I. Weitz, Jack Hirsh, Edward Young
-
Patent number: 5688507Abstract: Thrombus or clot formation and accretion are inhibited by administering thrombin-displacing substances to a patient. The thrombin-displacing substances comprise either thrombin analogs which bind to the thrombin-binding site on fibrin or fibrin analogs which bind to a fibrin-binding site on thrombin. By displacing the thrombin from clot or thrombus, the thrombin is released into circulation where it is inactivated by endogenous anti-proteinases. The fibrin analogs which bind to the fibrin-binding site on thrombin may be linked to a second binding moiety which binds to and/or inactivates the catalytic site on thrombin to further inhibit thrombosis.Type: GrantFiled: November 13, 1995Date of Patent: November 18, 1997Assignee: Hamilton Civic Hospitals Research Development, Inc.Inventors: Jeffrey I. Weitz, Jack Hirsh